A Bordetella pertussis acellular vaccine candidate: antigenic characterization and antibody induction.
A single-step chromatography on Matrex-Gel Blue A has been employed to obtain soluble extracts containing some of the most important antigens of Bordetella pertussis, pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (69-kDa outer membrane protein), fimbriae (FIM2 and FIM3) and adenylate cyclase (AC). Two supernatants, P19 (48.8 mg PT, 6.8 mg FHA, 17.3 mg AC, 13 mg FIM2 and 4.9 mg FIM3 per liter) and P21 (0.1 mg PT, 0.07 mg FHA, 0.46 mg FIM2 and 0.94 mg FIM3 per liter), resulting from bacteria grown in Stainer-Scholte medium, were submitted to chromatography. Fractions with the antigens were obtained after stepwise elution with 60 mM sodium phosphate buffer, pH 6.0; 50 mM Tris-HCl, pH 7.4; 50 mM Tris-HCl, pH 7.4/0.75 M MgCl2; 50 mM Tris-HCl, pH 7.4/4 M MgCl2 and 4 M urea. Preparations from P19 (containing 4.05 micrograms PT, 8.14 micrograms FHA, 6.3 micrograms AC, 3.37 micrograms 69-kDa, 9.54 micrograms FIM2 and 2.23 micrograms FIM3) and from P21 (with 0.175 micrograms PT, 0.28 micrograms FHA, 0.002 micrograms 69-kDa, 0.005 micrograms FIM2 and 0.122 micrograms FIM3) were detoxified with glutaraldehyde and tested as an acellular pertussis vaccine. These products were non-toxic for mice and induced high levels of antibodies against purified pertussis antigens, as judged by ELISA.
Dias
W O
WO
Centro de Biotecnologia, Instituto Butantan, São Paulo, Brasil.
Horton
D S
DS
Takahashi
C M
CM
Raw
I
I
D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology; D000917:Antibody Formation; D000942:Antigens, Bacterial / Q000032:analysis*; D001886:Bordetella pertussis / Q000276:immunology* / Q000472:pathogenicity; D002846:Chromatography, Affinity; D004797:Enzyme-Linked Immunosorbent Assay; D051379:Mice; D010567:Pertussis Vaccine; D013997:Time Factors
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D010567:Pertussis Vaccine